Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data

Bitget2026/09/30 12:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eupraxia Pharmaceuticals released new long-term results from its Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis.
Data were presented as an update now, showing symptom relief that generally held up for up to a year in higher-dose cohorts.
Patients also showed tissue-level improvement consistent with earlier readouts, supporting the case for a long-acting, locally delivered steroid approach.
Safety remained supportive, with no treatment-related serious adverse events reported to date in the open-label study.
A separate randomized Phase 2b RESOLVE study is recruiting; interim results are expected in December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONECNPR____9836563) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data

You may also like

Crypto prices